Metastatic Castration-Resistant Prostate Cancer Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Metastatic Castration-Resistant Prostate Cancer remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 540 matched trial records and 1,801 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07698535 | Docetaxel + Lutetium (177 Lu) Vipivotide Tetraxetan | Phase 2; Not yet recruiting | University of Washington | United States | Number and proportion among those recruited with detectable circulating tumor deoxyribonucleic acid (ctDNA) tumor fraction who undergo randomization (Up to 2 cycles (Cycle length = 6 weeks)); Number of patients screened, enrolled, evaluable for C2D1 ctDNA tumor fraction and for who cycle 3 is administered (Up to cycle 3 administration (Cycle length = 6 weeks)) | 2029-07-05 |
| NCT07697989 | Intervention not normalized | Not Applicable; Not yet recruiting | Novartis Pharmaceuticals Canada, Inc. | Geography not listed | Real-World Overall Survival (rwOS) (Up to approximately 3 years); Median rwOS (Up to approximately 3 years) | 2026-10-31 |
| NCT07691697 | Intervention not normalized | Not Applicable; Recruiting | Sponsor not listed | Poland | Time to Next Systemic Therapy Escalation (From start of index progression-directed radiotherapy to initiation of a new…) | 2030-12-30 |
| NCT07682649 | Technetium Tc-99M Sulfur Colloid + Gallium GA-68 Gozetotide + Lutetium (177 Lu) Vipivotide Tetraxetan | Phase 1; Not yet recruiting | Rogel Cancer Center: University of Michigan | United States | Dose limiting toxicity (DLT) (up to 6 weeks) | 2027-08-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Role of CAR-T cell therapy in prostate cancer: A systematic review and meta-analysis. (Not Applicable): the indexed record reports CRS(≥Grade 3) = 9.2 %.
- Sequencing of PARP inhibitors and taxane chemotherapy in HRR-altered metastatic castration-resistant prostate cancer: A real-world VA analysis. (Not Applicable): the indexed record reports OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85); OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85); OS: HR = 1.09(95.0% CI, 0.84 - 1.41); HR = 0.9(95.0% CI, 0.41 - 1.85).
- Evaluation of the safety, efficacy and dosimetry of TRC003 in metastatic castration-resistant prostate cancer: A prospective, open-label, single-arm study. (Phase 1): the indexed record reports AE = The most common AE was anemia (80%) and dry mouth (73.3%).; AE = The most common AE was anemia (80%) and dry mouth (73.3%)..
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Docetaxel (Approved; Tubulin), Lutetium (177 Lu) Vipivotide Tetraxetan (Approved; PSMA), Technetium Tc-99M Sulfur Colloid (Approved), Gallium GA-68 Gozetotide (Approved; PSMA). Company & Deal Intelligence records identify sponsor context for University of Washington, Novartis Pharmaceuticals Canada, Inc., Rogel Cancer Center: University of Michigan. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Metastatic Castration-Resistant Prostate Cancer has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
